Trial site
Weifang NO.2 People's Hospital
Weifang, 261041, ChinaNot linked to an institution yet
The trials here
What the 9 trials at this site are about, from their registry records.
- Status
- Recruiting4 trials
- Not yet recruiting3 trials
- Active, not recruiting2 trials
- Lead sponsor
- Akeso2 trials
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 trials
- Biotheus Inc.1 trial
- Gilead Sciences1 trial
- Hoffmann-La Roche1 trial
- and 2 more
Running trials
Recruiting
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
NCT07827599· Phase 3· Hoffmann-La Roche· Source
Recruiting
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Guoru Yang, Bachelor
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Guoru Yang, Bachelor
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Contact: Kunning Yang, M.D.
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Suting Xi, Master
Active, not recruiting
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort
NCT06649721· Phase 3· Huashan Hospital· Source
Active, not recruiting
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532· Phase 3· Biotheus Inc.· Source
Not yet recruiting
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127· Phase 3· Akeso· Source
Contact: Zhifang Yao, M.D.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error